RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
RenovoRx, Inc. (RNXT)
Company Research
Source: GlobeNewswire
MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that its abstract submission to the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting has been accepted. The meeting will be held February?4–8,?2026 in Savannah, Georgia. Researchers including Christopher Laing, MD of Sutter Health in California, will present the clinical data abstract, “Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors.” The study explores a simplified method for measuring intra-arterial pressure during procedures that use the TAMP (Trans-Arterial Micro-Perfusion) therapy platform enabled by RenovoCath catheter, a double-balloon drug-delivery device, and
Show less
Read more
Impact Snapshot
Event Time:
RNXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNXT alerts
High impacting RenovoRx, Inc. news events
Weekly update
A roundup of the hottest topics
RNXT
News
- RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial OfficerGlobeNewswire
- RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific MeetingGlobeNewswire
- RenovoRx (NASDAQ:RNXT) was upgraded by analysts at Jones Trading to a "strong-buy" rating.MarketBeat
- RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer CenterGlobeNewswire
- Loss-Making RenovoRx, Inc. (NASDAQ:RNXT) Expected To Breakeven In The Medium-Term [Yahoo! Finance]Yahoo! Finance
RNXT
Earnings
- 5/15/25 - In-Line
RNXT
Sec Filings
- 2/6/26 - Form 8-K
- 1/30/26 - Form SCHEDULE
- 1/22/26 - Form 4
- RNXT's page on the SEC website